bexmarilimab   Click here for help

GtoPdb Ligand ID: 12907

Synonyms: Clevegen | FP-1305 | FP1305
Immunopharmacology Ligand
Compound class: Antibody
Comment: Bexmarilimab (FP-1305; Faron Pharmaceuticals) is a humanized anti-CLEVER-1 (stabilin 1; STAB1) IgG4-antibody [1]. It switches immunosuppressive M2 macrophages to immune-stimulating M1 macrophages, activates T cells and restores T cell-dependent killing of cancer cells. Bexmarilimab is a cancer immunotherapy clinical candidate [2].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Hollmén M, Maksimow M, Rannikko JH, Karvonen MK, Vainio M, Jalkanen S, Jalkanen M, Mandelin J. (2022)
Nonclinical Characterization of Bexmarilimab, a Clever-1-Targeting Antibody for Supporting Immune Defense Against Cancers.
Mol Cancer Ther, 21 (7): 1207-1218. [PMID:35500016]
2. Virtakoivu R, Rannikko JH, Viitala M, Vaura F, Takeda A, Lönnberg T, Koivunen J, Jaakkola P, Pasanen A, Shetty S et al.. (2021)
Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial.
Clin Cancer Res, 27 (15): 4205-4220. [PMID:34078651]